BBI-355

N/A

Report date: 2024/04/09 11:27:59
NME

Base Information

Drug NameBBI-355
Drug Alias NameBBI-355
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA modulatorsCheckpoint kinase 1 inhibitors
TargetsDNACheckpoint kinase 1
Therapy Area/IndicationsUterine Cervical NeoplasmsSmall Cell Lung CarcinomaOvarian Neoplasms +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBoundless Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesBoundless Bio Inc
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsSmall Cell Lung CarcinomaOvarian Neoplasms +[12] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A